Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

Eli Lilly recently reported positive topline Phase 3 results from TRANSCEND-T2D-1, showing that its investigational triple agonist retatrutide significantly lowered A1C and reduced body weight over 40 ...

Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes: Indianapolis Friday, March 20, ...

The investment thesis for Viking Therapeutics now hinges on a single, high-stakes clinical event, according to market ...

Further weight loss details are yet to come this year, but Eli Lilly and Co. scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, ...

Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume if the medication was not held prior to upper endoscopy, unless they were on a clear liquid diet the previous day, ...

Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.

Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

A new class of weight loss drug just took a major step toward approval for use. In a phase III clinical trial, medication ...